The IPKat

The enablement paradox and the danger of definitions (Wyeth v AstraZeneca)

Be careful what you wish for: Method of treatment claim for an antibody genus found to satisfy both written description and enablement requirement (Teva v Eli Lilly)

[Guest Post] What the Inari vs. Corteva case really tells us about enablement of plant inventions

Strict US written description and enablement requirement applied to ADCs and platform inventions (Seagen v Daiichi Sankyo)

Non-reproducible prior art post-G 1/23: Novelty versus inventive step (T 1044/23)

Will functional antibody inventions find new life in the US with mean-plus-function claims? (Ex parte Chamberlain, Appeal No. 2022-001944)

USPTO call for comments: Impact of AI on patentability

BGH on enablement: disclosure may be enabling without being novelty destroying